文献速递冠心病心律失常

神经肽Y在ST段抬高型心肌梗死后的促心律失常作用及Y1受体拮抗剂的协同抗心律失常潜力

The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.
PubMed 文献 · Eur Heart J · 2020-01-01

在78例行直接PCI的STEMI患者中,6例(7.7%)48小时内发生持续性室速或室颤,其静脉NPY水平显著更高(P<0.05),NPY阈值27.3 pg/mL的敏感度0.83、特异度0.71;大鼠离体心脏及细胞实验显示,即使最大剂量美托洛尔阻断β受体,NPY仍通过Y1受体增加钙瞬变幅度、缩短时程并降低室颤阈值,Y1拮抗剂BIBO3304可预防上述效应。

要点

  • STEMI后48小时内发生持续性室速/室颤者静脉NPY水平显著更高。
  • NPY阈值27.3 pg/mL对预测室速/室颤的敏感度0.83、特异度0.71。
  • Y1受体拮抗剂BIBO3304与β受体阻滞剂协同抗心律失常。

核心结论

  • 交感神经共递质NPY在交感刺激时释放,作为新的心律失常触发因素。
  • 抑制Y1受体的药物与β受体阻滞剂协同,可作为新型抗心律失常治疗。

研究设计与样本

  • 研究纳入78例行直接经皮冠状动脉介入治疗的STEMI患者,观察48小时内持续性室速或室颤发生情况。
  • 采用大鼠离体Langendorff灌注心脏、星状神经节刺激及光学标测电压和钙,并用Y1受体拮抗剂BIBO3304干预。
  • 实验性ST段抬高缺血再灌注模型比较NPY(250 nmol/L)与对照的室速/室颤发生率。

主要发现

  • 78例患者中6例(7.7%)在48小时内发生持续性室速或室颤。
  • 发生室速/室颤的患者静脉NPY水平显著更高(P<0.05),且无晚期就诊、更大梗死面积和β受体阻滞剂使用等经典危险因素。
  • NPY阈值27.3 pg/mL的敏感度0.83、特异度0.71。
  • 人及大鼠星状神经节中检测到NPY mRNA;大鼠星状神经节10 Hz、2分钟刺激导致显著NPY释放。
  • 最大剂量美托洛尔(10 μmol/L)下,NPY仍增加钙瞬变幅度、缩短钙瞬变时程并显著降低室颤阈值,BIBO3304(1 μmol/L)可预防。

关键数值与推荐

  • 静脉NPY阈值27.3 pg/mL,敏感度0.83、特异度0.71。
  • 美托洛尔浓度10 μmol/L,BIBO3304浓度1 μmol/L,NPY浓度250 nmol/L。
  • NPY(250 nmol/L)组室速/室颤发生率60%,对照组10%。

临床怎么用

  • STEMI患者即使使用β受体阻滞剂,仍需关注NPY介导的残余心律失常风险。
  • Y1受体拮抗剂可能作为与β受体阻滞剂协同的新型抗心律失常策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: ST-elevation myocardial infarction is associated with high levels of cardiac sympathetic drive and release of the co-transmitter neuropeptide Y (NPY). We hypothesized that despite beta-blockade, NPY promotes arrhythmogenesis via ventricular myocyte receptors. METHODS AND RESULTS: In 78 patients treated with primary percutaneous coronary intervention, sustained ventricular tachycardia (VT) or fibrillation (VF) occurred in 6 (7.7%) within 48 h. These patients had significantly (P < 0.05) higher venous NPY levels despite the absence of classical risk factors including late presentation, larger infarct size, and beta-blocker usage. Receiver operating curve identified an NPY threshold of 27.3 pg/mL with a sensitivity of 0.83 and a specificity of 0.71. RT-qPCR demonstrated the presence of NPY mRNA in both human and rat stellate ganglia. In the isolated Langendorff perfused rat heart, prolonged (10 Hz, 2 min) stimulation of the stellate ganglia caused significant NPY release. Despite maximal beta-blockade with metoprolol (10 μmol/L), optical mapping of ventricular voltage and calcium (using RH237 and Rhod2) demonstrated an increase in magnitude and shortening in duration of the calcium transient and a significant lowering of ventricular fibrillation threshold. These effects were prevented by the Y1 receptor antagonist BIBO3304 (1 μmol/L). Neuropeptide Y (250 nmol/L) significantly increased the incidence of VT/VF (60% vs. 10%) during experimental ST-elevation ischaemia and reperfusion compared to control, and this could also be prevented by BIBO3304. CONCLUSIONS: The co-transmitter NPY is released during sympathetic stimulation and acts as a novel arrhythmic trigger. Drugs inhibiting the Y1 receptor work synergistically with beta-blockade as a new anti-arrhythmic therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kalla M, Hao G, Tapoulal N, et al. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J. 2020. PMID: 31834357. doi:10.1093/eurheartj/ehz852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。